TL;DR
This Phase 2 study investigated the combination of sintilimab (an anti-PD-1 antibody) and anlotinib (a multi-target tyrosine kinase inhibitor) as a first-line treatment for advanced hepatocellular carcinoma (HCC). The combination demonstrated promising clinical activity, including a notable objective response rate and median progression-free survival, with a manageable safety profile.
What Problem Does This Paper Address?
Hepatocellular carcinoma (HCC) is a significant global health challenge, often diagnosed at advanced stages where curative treatments like surgery are not feasible. Current first-line treatments, such as tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, offer modest benefits and can have significant side effects. While immune checkpoint inhibitors (ICIs) have shown promise in later lines of treatment, their efficacy as a first-line therapy for HCC has been less definitive. This paper addresses the need for more effective and safer first-line treatment options for advanced HCC by exploring the synergistic potential of combining an ICI (sintilimab) with a multi-target TKI (anlotinib), hypothesizing that this combination could overcome tumor-induced immune suppression and target tumor angiogenesis more effectively.
Methods
This was an open-label, single-arm, Phase 2 clinical trial conducted at Jiangsu Province Hospital. A safety run-in phase involving the first six participants was included to assess dose-limiting toxicities (DLTs). The primary endpoints were safety and objective response rate (ORR) as assessed by RECIST v1.1. Patients received sintilimab (200 mg) intravenously on day 1 and anlotinib (12 mg) orally once daily on days 1-14 of each 3-week cycle. Tumor response was evaluated every two cycles using both RECIST v1.1 and modified RECIST (mRECIST). Adverse events were graded according to NCI CTCAE v5.0. Biomarker analyses included plasma alpha-fetoprotein (AFP), lactate dehydrogenase (LDH), circulating CD16+CD56+ NK cells, and the Controlling Nutritional Status (CONUT) score.
Datasets
This study utilized data from 20 patients with advanced hepatocellular carcinoma who were enrolled in the trial. The data collected included patient demographics, clinical characteristics, treatment outcomes (response rates, progression-free survival, overall survival), and biomarker data. No new public datasets were introduced.
Key Insights and Ideas
- Synergistic Potential: The combination of an anti-PD-1 antibody (sintilimab) and a multi-target TKI (anlotinib) shows promise as a first-line treatment for advanced HCC, suggesting a synergistic effect beyond monotherapy.
- Manageable Toxicity: While all patients experienced treatment-related adverse events (TRAEs), the majority were of any grade, and grade 3 TRAEs were manageable. Importantly, no grade 4/5 TRAEs were reported, indicating a favorable safety profile compared to some existing treatments.
- Biomarker Associations: Several factors were identified as potentially predictive of better outcomes:
- Immune-Related Adverse Events (irAEs): Patients experiencing irAEs had significantly longer median progression-free survival (PFS).
- Grade 3 TRAEs: Similarly, patients with grade 3 TRAEs also showed longer median PFS.
- CONUT Score: A lower CONUT score (≤2) was associated with significantly longer median PFS, suggesting that nutritional status might be a useful prognostic marker.
- LDH Levels: Lower baseline LDH levels were linked to longer median PFS.
- AFP Response: A greater reduction in AFP levels post-treatment was associated with longer treatment duration and a trend towards better PFS.
- NK Cell Activity: A higher proportion of CD16+CD56+ NK cells at baseline was associated with better treatment response (CR or PR).
Key Results
- Objective Response Rate (ORR): The ORR was 35.0% (95% CI 15.4%-59.2%) per RECIST v1.1 and 55.0% (95% CI 31.5%-76.9%) per modified RECIST.
- Disease Control Rate (DCR): The DCR was 95.0% for both RECIST v1.1 and modified RECIST.
- Median Progression-Free Survival (PFS): The median PFS was 12.2 months (95% CI, 3.8 to not reached) for both assessment criteria.
- Median Overall Survival (OS): The median OS was not reached (95% CI, 16.3 months to NR).
- Adverse Events: All 20 patients experienced TRAEs. Grade 3 TRAEs occurred in 8 (40.0%) patients, most commonly decreased platelet count and increased γ-glutamyl transferase. Five (25%) patients developed immune-related AEs.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-Arm Study: The study design is a single-arm Phase 2 trial, which limits definitive conclusions about efficacy due to the absence of a control group.
- Small Sample Size: The study enrolled only 20 patients, which restricts the statistical power and generalizability of the findings.
- Single Institution: Data were collected from a single center, which may introduce institutional biases.
- COVID-19 Pandemic: The ongoing COVID-19 pandemic impacted patient enrollment and treatment, potentially affecting the study's progression.
Future work should focus on:
- Randomized Controlled Trials: Larger, randomized controlled trials are needed to confirm the efficacy and safety of sintilimab plus anlotinib as a first-line treatment for advanced HCC.
- Biomarker Validation: Further investigation and validation of the identified potential biomarkers (AFP response, LDH levels, CONUT score, NK cell activity, irAEs) are crucial for patient stratification and personalized treatment strategies.
- Exploration of Combinations: Continued exploration of various combinations of immunotherapeutic agents and antiangiogenic molecules is warranted.
Summary updated